INTRODUCTION
Berenil and Pentamidine are structural analogues of MGBG ( Fig. 1) , which is a potent reversible inhibitor of putrescine-stimulated ADC (Williams-Ashman & Schenone, 1972) , present in higher eukaryotes (Poso et al., 1976) , but not a good inhibitor of putrescine-insensitive ADC (Poso et al., 1975b; Pegg & Jacobs, 1983) or Mg2+-stimulated prokaryotic ADC. Pegg and co-workers have shown (Pegg & Conover, 1976; Pegg, 1978 ) that a derivative of MGBG, MBAG ( Fig. 1) , is a potent irreversible inhibitor of putrescine-stimulated ADCs. Both MGBG (Kay & Pegg, 1973; Otani et al., 1974; Fillingame & Morris, 1973; Jainne et al., 1978; WilliamsAshman & Canellakis, 1979) and MBAG (Wiegand & Pegg, 1978; Alhonen-Hongisto et al., 1980; H6lttii et al., 1981) have been used to inhibit cell growth, both in vivo and in vitro.
In the present paper we describe the irreversible inhibition of ADC by Berenil, a drug widely used in veterinary and human medicine as an anti-babesial (blood parasites) and anti-trypanosomal agent (Newton, 1972; Robertson, 1977) , and the irreversible inhibition of ADC by Pentamidine, a drug used to cure infections caused by Pneumocystis carinii (DeVita et al., 1969; Hughes, 1979) . 
Sources of adenosylmethionine decarboxylases
Crude ADCs from rat liver (Poso & Pegg, 1982) , yeast (P6so et al., 1975b) and Pseudomonas aeruginosa (P6so et al., 1976) were prepared by published methods cited. Highly purified rat liver ADC was prepared as described by Poso & Pegg (1982) . The specific activity of the final preparation of ADC was more than 500 units/mg of protein (Poso & Pegg, 1982) and the preparation gave a single band when analysed by polyacrylamide-gel electrophoresis under denaturing conditions as described by Pos6 & Pegg (1982) . About 0.03 unit was used in each assay. When DEAE-cellulose fraction was used (Tables 2  and 3 ) below, it was purified exactly as described by Poso & Pegg (I982) and the-specific activity-of the preparation was 6.1 units/mg of protein. About 0.05 unit was used in each assay. Liver extracts for ADC determinations ( Fig. 2 below) were prepared by homogenizing livers in 2 vol. of ice-cold 25 mM-sodium phosphate buffer, pH 7.5, containing 2.5 mM-putrescine, 1 mMdithiothreitol and 0.1 mM-EDTA (standard buffer) and then centrifuging at 42 000 g for 45 min. The supernatants were freed from low-Mr materials by addition of (NH4)2SO4 to 70 O saturation. The resulting precipitates were dissolved in a small volume of standard buffer and dialysed overnight at 4°C against 500 vol. of the same buffer and then assayed for ADC.
Treatment of rats
To induce ADC in rat liver for the purification of the enzyme, 45 rats were treated with MGBG exactly as described by Poso & Pegg (1982) . Berenil (50 mg/kg body weight) was injected intraperitoneally in 0.9% NaCl in a volume of 0.5 ml.
Analytical methods
The activity of eukaryotic ADC was measured as described by Pegg & Poso (1983) . When bacterial enzyme was assayed, the putrescine in the assay medium was replaced by 5 mM-MgCl2 (Wickner et al., 1970) . Protein was determined by the method of Bradford (1976) . Table 1 shows the effect of Berenil and Pentamidine on crude and homogeneous rat liver, crude yeast and P. aeruginosa ADCs. A clear inhibition of the rat and yeast enzymes was exerted by 10 /sM-Berenil before dialysis of the samples, and the degree of the inhibition did not change after dialysis. This shows that the inhibition seen is not due to traces of the drug not removed by dialysis. Table 1 also shows that the sensitivity of highly purified rat liver ADC to Berenil was similar to that of the crude enzyme, suggesting that the effect of Berenil is not mediated by any hypothetical factor(s) present in rat liver cytosol. Furthermore, Table 1 shows that bacterial ADC was less severely affected by the drug, some activity remaining in the presence of 1 mM-Berenil before and after dialysis. Table also shows that a nearly 100 times higher concentration of Pentamidine was needed to achieve the degree of inhibition caused by Berenil. Again the prokaryotic ADC needed a higher concentration of Pentamidine for its inhibition than did the eukaryotic ADC (Table 1) . Table 2 shows the effect of 100 /tM-Berenil on partially purified (DEAE-cellulose fraction; Poso & Pegg, 1982) rat liver ADC in the presence or absence of various concentrations of putrescine or adenosylmethionine. Putrescine did not protect the enzyme against Berenil when the enzyme preparation was incubated for 30 min in the presence of Berenil and then dialysed overnight. On the other hand, the substrate adenosylmethionine, with putrescine (Table 2) or alone (result not shown), partially protectedtheenzymeagainstBerenil-inducedinactivation. This is similar to the observation by Pegg (1978) that adenosylmethionine can protect ADC against MBAG. Crude ADC preparations and homogeneous rat liver ADC, obtained as described in the Experimental section, were incubated with Berenil or Pentamidine for 30 min at 37°C and then the activity was measured either directly ('Not dialysed') or after dialysing the samples overnight against 500 vol. of standard buffer ('Dialysed'). Controls without any drug lost less than 10% of activity during this process. After dialysis, enzymic activity was assayed as described in the Experimental section. Initial specific activities of the preparations (pmol of CO2 formed/30 min per mg of protein) were: crude rat liver, 240; homogeneous rat liver, Possibly Berenil and MBAG can react similarly with the enzyme.
RESULTS
Since Newton (1972) has reported that 4,4'-diamidinodiphenylamine, which is a close structural analogue of Berenil (Fig. 1) , is an anti-babesial drug, we also tested the effect of this drug on partially purified rat liver ADC. Table 3 shows that when ADC was measured in non-dialysed samples, it was inhibited by 4,4'-diamidinodiphenylamine, although less strongly (410% of activity remaining at 1 mM-drug) than Berenil. However, unlike that of Berenil, the effect of4,4'-diamidinodiphenylamine, even after 2 h incubation with the drug, could be reversed by dialysis (Table 3 ), indicating that the drug does not react with the enzyme in an irreversible manner. These results suggest that there may have to be a critical distance between the diamidino groups in Berenil and its analogues for their inhibitions to be irreversible. It is also possible that it may be a property of the diazide group, rather than just the distance between the ends of the molecule, that affects the magnitude of the inhibition.
In order to determine whether Berenil also has an effect on ADC activity in vivo (i.e. does it penetrate the cells), it was injected intraperitoneally into rats. Fig. 2 shows that after a single dose of Berenil (50 mg/kg body wt.) there was a considerable irreversible loss of the activity ofADC as judged by measuring the activity in (NH4)2S04 precipitates which were dialysed overnight (see the Experimental section). Activity was inhibited within 3 h and then maintained at a lower level for 12 h, whereafter it started to rise to the control level 24 h after the injection (Fig. 2) . In this connection it should be mentioned that Pentamidine had a tiny inhibitory effect (10%) on ADC in vivo when injected at a dose of 80 mg/kg in rat liver and measured 24 h later (results not shown), thus perhaps reflecting its weak ability to inhibit ADC in vitro (Table 1) .
DISCUSSION
MGBG has commonly been used in polyamine research to inhibit growth under experimental conditions (Janne et al., 1978) , and in clinical trials for the treatments of cancer patients (Yap et al., 1981; Jiinne et al., 1983) . The usefulness of MGBG has been questioned, since it is a toxic compound and is known to affect both mitochondrial structure and function (Porter et al., 1979; Byczkowski & Porter, 1983) in addition to polyamine (H6ltta et al., 1973; Karvonen & Pos6, 1984) and DNA (Brown et al., 1975; Poso & Kuosmanen, 1983) metabolism. MBAG (Pegg, 1978; Wiegand & Pegg, 1978) was synthesized in the hope offinding more suitable drugs to inhibit spermidine biosynthesis, but it has not been used in clinical trials. This paper shows that a long-used babesicidal and trypanocidal agent, Berenil, inhibits polyamine biosynthesis, at least in vitro (Table 1 ). The mode of the anti-protozoal action of Berenil is unknown, but it is believed that it is partially due to a selective inhibition of kinetoplast DNA synthesis (Newton, 1972; Newton & LePage, 1967) . Waring (1970) has shown that Berenil binds to closed circular DNA and can replace spermidine in DNA, suggesting a specific effect by Berenil on the function of spermidine. Interestingly Bacchi and coworkers McCann et al., 1983) have shown that the curative effect of Berenil is blocked by spermidine in Trypanosoma brucei infection, suggesting a mechanism in which spermidine is directly involved.
In the case of Pentamidine it is difficult to make any interpretations relating to its clinical actions and any possible effects on polyamine biosynthesis, since the plasma and tissue levels after a clinical dose of Pentamidine (plasma levels are 0.7-2.3 /tM; Waalkes & DeVita, 1970) are very much lower than needed for the inhibition of ADC in vitro (Table 1) . Unfortunately, there are no published data available on the concentration of Berenil in plasma after the treatment with the drug. However, as in the case of Berenil, Bacchi et al. (1983) have shown that spermidine and spermine reverse the trypanocidal effect of Pentamidine. Moreover, they showed , by using [3H]Pentamidine, that the reversal by polyamines was not simply due to inhibition of the uptake of the drug, but was a more complex process taking place intracellularly. Bachrach et al. (1983) have shown that Pentamidine lowered the concentration of polyamines in the skin of mice infected with Leishmania. This hints at an attractive possibility that Berenil and Pentamidine (and other trypanocidal diamidines; Bacchi et al., 1981; Ulrich & Cerami, 1984) may have some specificity against protozoal (putrescine-insensitive; Poso et al., 1975a) ADC. Further studies are needed to compare the effect of Berenil and its derivatives on putrescine-insensitive and on putrescine-sensitive ADCs.
It was interesting to see how critical is the distance between the diamidino groups attached to the benzene rings of drugs of the Berenil type. Even the removal of the azo group (Fig. 1 ) from Berenil gives a compound (4,4'-diamidinodiphenylamine; Fig. 1 ) that is a weaker inhibitor of ADC than Berenil itself and inhibits reversibly. On the other hand, Pentamidine, with a long chain between the benzene rings ( Fig. 1) was an irreversible inhibitor of ADC, although weaker than Berenil. This suggests that Berenil and Pentamidine are able to penetrate the active site of the enzyme and then react, probably bivalently, to form a rather stable enzyme-inhibitor complex. 4,4'-Diamidinodiphenylamine appears to enter the active site, but is not big enough to react to form an irreversible complex with the enzyme. Most probably the active site is involved in the binding of inhibitor, since the substrate adenosylmethionine partially protected ADC against Berenil.
Further studies are needed both to ascertain whether the anti-protozoal effects of cationic diamidines are at least partially mediated via the inhibition of spermidine biosynthesis, and to reveal the mechanism(s) by which these compounds cause the irreversible inhibition of ADC.
